Rallybio Corporation (RLYB)
NASDAQ: RLYB
· Real-Time Price · USD
0.56
0.05 (9.46%)
At close: Oct 03, 2025, 3:59 PM
0.57
1.12%
After-hours: Oct 03, 2025, 07:54 PM EDT
9.46% (1D)
| Bid | 0.55 |
| Market Cap | 23.61M |
| Revenue (ttm) | 761K |
| Net Income (ttm) | -41.65M |
| EPS (ttm) | -0.88 |
| PE Ratio (ttm) | -0.64 |
| Forward PE | -0.48 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 0.57 |
| Volume | 929,608 |
| Avg. Volume (20D) | 2,942,452 |
| Open | 0.55 |
| Previous Close | 0.51 |
| Day's Range | 0.54 - 0.60 |
| 52-Week Range | 0.22 - 1.24 |
| Beta | -1.10 |
| Ex-Dividend Date | n/a |
About RLYB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RLYB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RLYB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsRallybio Corporation is scheduled to release its earnings on
Nov 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+3.59%
RLYB stock has given up its prior gain. Rallybio s...
Unlock content with
Pro Subscription
1 month ago
+3.59%
Rallybio shares are trading higher after the company received a $12.5M equity milestone payment from Recursion following the initiation of preclinical studies for REV102.
2 months ago · businesswire.com
Rallybio Sells Interest in REV102 Program to Recursion PharmaceuticalsNEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...